Review and analysis of history and utilization of panretinal photocoagulation and ranibizumab after publication of protocol S.

IF 3 2区医学 Q1 OPHTHALMOLOGY

Current Opinion in Ophthalmology Pub Date : 2024-09-01 Epub Date: 2024-07-12 DOI:10.1097/ICU.0000000000001076

Serena Shah, Brandon Chou, Marissa Patel, Arjun Watane, Lea Shah, Nicolas Yannuzzi, Jayanth Sridhar

{"title":"Review and analysis of history and utilization of panretinal photocoagulation and ranibizumab after publication of protocol S.","authors":"Serena Shah, Brandon Chou, Marissa Patel, Arjun Watane, Lea Shah, Nicolas Yannuzzi, Jayanth Sridhar","doi":"10.1097/ICU.0000000000001076","DOIUrl":null,"url":null,"abstract":"Purpose of review: We describe the history, utilization, and series results of panretinal photocoagulation (PRP) and ranibizumab and provide an analysis of PRP and ranibizumab usage before versus after the publication of the 2-year and 5-year results of the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol S trial.Recent findings: Number of ranibizumabs performed began to increase and number of PRPs performed began to decrease in 2016. After publication of the 2-year results, there was significant negative trend in PRP services and significant positive trend in ranibizumab services (both P < 0.001). After publication of the 5-year results, there was significant negative trend in PRP services (P = 0.003). There were significant negative trends (all P < 0.001) in reimbursement factors for PRP from 2013 to 2020: average work RVU (wRVU), nonfacility physical expense RVU, facility PE RVU, malpractice RVU (MP RVU).Summary: Both PRP and ranibizumab have undergone numerous trials comparing their efficacy to other treatment options or no treatment at all. The publication of the 2-year results of Protocol S was associated with an increase in utilization of ranibizumab and decrease in utilization of PRP, with continued decrease after the publication of the 5-year results.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"35 5","pages":"369-375"},"PeriodicalIF":3.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ICU.0000000000001076","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: We describe the history, utilization, and series results of panretinal photocoagulation (PRP) and ranibizumab and provide an analysis of PRP and ranibizumab usage before versus after the publication of the 2-year and 5-year results of the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol S trial.

Recent findings: Number of ranibizumabs performed began to increase and number of PRPs performed began to decrease in 2016. After publication of the 2-year results, there was significant negative trend in PRP services and significant positive trend in ranibizumab services (both P < 0.001). After publication of the 5-year results, there was significant negative trend in PRP services (P = 0.003). There were significant negative trends (all P < 0.001) in reimbursement factors for PRP from 2013 to 2020: average work RVU (wRVU), nonfacility physical expense RVU, facility PE RVU, malpractice RVU (MP RVU).

Summary: Both PRP and ranibizumab have undergone numerous trials comparing their efficacy to other treatment options or no treatment at all. The publication of the 2-year results of Protocol S was associated with an increase in utilization of ranibizumab and decrease in utilization of PRP, with continued decrease after the publication of the 5-year results.

查看原文本刊更多论文

在 S.方案公布后，对泛视网膜光凝术和雷尼珠单抗的历史和使用情况进行回顾和分析。

综述目的：我们描述了泛视网膜光凝（PRP）和雷尼珠单抗的历史、使用情况和系列结果，并对糖尿病视网膜病变临床研究网络（DRCR.net）S协议试验2年和5年结果公布前后的PRP和雷尼珠单抗使用情况进行了分析：2016年，雷尼布单抗的使用次数开始增加，PRP的使用次数开始减少。2 年结果公布后，PRP 服务呈显著的负趋势，而雷尼珠单抗服务呈显著的正趋势（均为 P 摘要：PRP 和雷尼珠单抗都经过了大量试验，比较了它们与其他治疗方案或根本不进行治疗的疗效。S 方案 2 年结果公布后，使用雷尼珠单抗的人数增加，使用 PRP 的人数减少，5 年结果公布后，使用 PRP 的人数继续减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Ophthalmology 医学-眼科学

CiteScore

6.80

自引率

5.40%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Ophthalmology is an indispensable resource featuring key up-to-date and important advances in the field from around the world. With renowned guest editors for each section, every bimonthly issue of Current Opinion in Ophthalmology delivers a fresh insight into topics such as glaucoma, refractive surgery and corneal and external disorders. With ten sections in total, the journal provides a convenient and thorough review of the field and will be of interest to researchers, clinicians and other healthcare professionals alike.